https://www.selleckchem.com/pr....oducts/pkm2-inhibito
PRNCR1 regulated CCND2 expression by competitively binding to miR-377. CCND2 activated the MEK/MAPK pathway, and after treatment with Mirdametinib, the MEK/MAPK pathway was inhibited, which was found to retard breast cancer growth. Our study highlights that lncRNA PRNCR1 may competitively bind to miR-377, leading to upregulated CCND2, which in turn activated MEK/MAPK pathway to promote breast cancer growth. Our study highlights that lncRNA PRNCR1 may competitively bind to miR-377, leading to upregulated CCND2, which i
Like
Comment
Share
